Patents by Inventor Nolwenn Martin

Nolwenn Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200102297
    Abstract: The present invention relates to a polymorphic form of masitinib mesylate, processes for its preparation, pharmaceutical compositions comprising it and their medical use.
    Type: Application
    Filed: March 22, 2018
    Publication date: April 2, 2020
    Applicant: Sandoz AG
    Inventors: Nolwenn Martin, Diana Fischer-Daut
  • Publication number: 20200022980
    Abstract: The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprising said solid dispersion and one or more additional pharmaceutical acceptable excipient(s), wherein the pharmaceutical composition can be used as a medicament, in particular for the treatment of endometriosis and uterine fibroids.
    Type: Application
    Filed: April 11, 2018
    Publication date: January 23, 2020
    Applicant: Sandoz AG
    Inventor: Nolwenn Martin
  • Publication number: 20190381085
    Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 19, 2019
    Applicant: Sandoz AG
    Inventor: Nolwenn Martin
  • Patent number: 10493089
    Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: December 3, 2019
    Assignee: Sandoz AG
    Inventor: Nolwenn Martin
  • Publication number: 20180271890
    Abstract: A solid pharmaceutical composition comprising a solid composition, wherein the solid com-position comprises sofosbuvir and at least one pharmaceutically acceptable matrix compound, wherein at least 99 weight-% of the sofosbuvir comprised in the solid composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, wherein the solid composition contains the sofosbuvir in an amount of at least 25 weight-%, or at least 30 weight-%, or at least 35 weight-%, or at least 40 weight-% or at least 50 weight-% or at least 55 weight-% or preferably at least 5 weight-% based on the combined weight of the sofosbuvir and the at least one matrix com-pound, wherein in the adsorption-desorption isotherm of the at least one pharmaceutically acceptable matrix compound, the desorption mass difference minus the adsorption mass dif-ference at 75% relative humidity and 25° C. is less than 0.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 27, 2018
    Applicant: Sandoz AG
    Inventors: Franz Xaver SCHWARZ, Nolwenn MARTIN
  • Publication number: 20180008624
    Abstract: The present invention relates to novel pharmaceutical compositions comprising Ledipasvir and Sofosbuvir as well as to methods for their preparation.
    Type: Application
    Filed: February 10, 2016
    Publication date: January 11, 2018
    Applicant: Sandoz AG
    Inventors: Franz Xaver Schwarz, Georg ANKER, Nolwenn MARTIN
  • Publication number: 20170296570
    Abstract: A tablet comprising a polymorphic form of crystalline sofosbuvir having a moisture stability of at least 95% in an amount of at least 40 weight-%.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 19, 2017
    Applicant: Sandoz AG
    Inventors: Nolwenn Martin, Franz Schwarz, Georg Anker
  • Publication number: 20170100422
    Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.
    Type: Application
    Filed: April 2, 2015
    Publication date: April 13, 2017
    Applicant: SANDOZ AG
    Inventor: Nolwenn MARTIN
  • Patent number: 9534004
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 3, 2017
    Assignee: SANDOZ AG
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Publication number: 20160200750
    Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 14, 2016
    Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
  • Publication number: 20090030216
    Abstract: The invention relates to a method for producing chiral organic compounds by asymmetric catalysis, using ionic catalysts comprising a chiral catalyst anion. The claimed method is suitable for reactions which are carried out over cationic intermediate stages, such as iminium ions or acyl pyridinium ions. The invention enables the production of chiral compounds with high ee values, that until now could only be obtained by means of costly purification methods.
    Type: Application
    Filed: February 27, 2007
    Publication date: January 29, 2009
    Applicant: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Benjamin List, Sonja Mayer, Nolwenn Martin, Xingwang Wang